Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05874713 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate Safety and Immunogenicity of Different Priming and Booster Regimens With Adjuvanted H5N8 and/or H5N6 Influenza Vaccine in Adults
A Phase 2 study, sponsored by Seqirus.
- Completed
- Registry status
- Phase 2
- Development phase
- 480
- Enrollment target
NCT05874713: Completed Phase 2 study, sponsored by Seqirus.
NCT05874713 is a Phase 2 study that has completed, run by Seqirus. The registered enrollment target is 480 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (261% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05874713, a Phase 2 study, has completed, sponsored by Seqirus.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 480 participants
- Enrollment target
Study Summary
This Phase 2, randomized, observer-blind clinical study is evaluating 3 different priming and booster regimens with MF59-adjuvanted H5N8 and/or H5N6 cell culture-derived influenza vaccine (aH5N8c; aH5N6c). Approximately 480 healthy adult subjects are to be randomized into 1 of 3 possible treatment groups, stratified by age group (18-64 years and ≥65 years) and by poultry worker status (yes/no). Each subject will receive a priming influenza vaccine injection on Day 1 and Day 22 and a booster vaccination on Day 202. Subjects will be followed up for approximately 6 months after the booster injection. The primary immunogenicity analysis is based on antibody responses against H5N8 and H5N6 as measured by hemagglutination inhibition (HI) assay on Day 1, Day 22, Day 29, Day 43, Day 202, Day 209 (H5N8 only), and Day 223.
Primary Outcome
GMT (HI) prevaccination
Interventions
- BIOLOGICAL aH5N6c on Day 1
- BIOLOGICAL aH5N6c on Day 22
- BIOLOGICAL aH5N8c on Day 1
- BIOLOGICAL aH5N8c on Day 22
- BIOLOGICAL aH5N8c on Day 202
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 480 participants |
| Start Date | 2023-06-07 |
| Est. Completion | 2024-09-25 |
| Phase | Phase 2 |
What the finished NCT05874713 record still lists
NCT05874713 is an interventional study that assigns participants to a tested intervention. The registered 480 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (261% higher).
The record links to 0 conditions, and to 5 interventions - of which aH5N6c on Day 1 is the first listed.
NCT05874713 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05874713 about?
NCT05874713 is a clinical study titled "Study to Evaluate Safety and Immunogenicity of Different Priming and Booster Regimens With Adjuvanted H5N8 and/or H5N6 Influenza Vaccine in Adults". This Phase 2, randomized, observer-blind clinical study is evaluating 3 different priming and booster regimens with MF59-adjuvanted H5N8 and/or H5N6 cell culture-derived influenza vaccine (aH5N8c; aH5N6c). Approximately 480 healthy adult subjects are to be randomized into 1 of 3 possible treatment g...
What is the current status of trial NCT05874713?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 480 participants. The study started on 2023-06-07. Estimated completion is 2024-09-25.
What interventions are being tested in trial NCT05874713?
The interventions under investigation include: aH5N6c on Day 1 (BIOLOGICAL), aH5N6c on Day 22 (BIOLOGICAL), aH5N8c on Day 1 (BIOLOGICAL), aH5N8c on Day 22 (BIOLOGICAL), aH5N8c on Day 202 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05874713?
This trial is sponsored by Seqirus, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05874713's enrollment target sits among peer trials
480 76th of 2000 higher than 1,924 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01954992 · 480 participants · Phase 3
Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
- NCT03023696 · 480 participants · NA
Can Prophylactic Foraminotomy Prevent C5 Palsy
- NCT04948060 · 480 participants · NA
Tribally Engaged Approaches to Lung Screening (TEALS)
- NCT05053230 · 480 participants · NA
A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI